NIBRT announce Julie O’Neill as Chairperson of NIBRT
NIBRT is delighted to announce the appointment of Julie O’Neill as the new Chairperson of our Board of Directors. Julie has been a valued member of the NIBRT Board since 2015, and has made significant contributions to our governance and strategy, particularly as Chair of the Audit and Risk Committee and through her expert input in developing our new strategy for 2024-2028.
Julie will be succeeding Brendan O’Callaghan, who has served as Chairperson of the Board since2012.
With over 20 years of executive experience in senior leadership roles in the pharmaceutical industry, including with Alexion Pharmaceuticals Inc. and Gilead Sciences, Julie brings a wealth of biopharmaceutical and governance knowledge and expertise to the role. Julie currently serves as an Independent Director on a number of private sector boards, including ICON plc, DBV Technologies SA, Hookipa Pharma Inc, Achilles Therapeutics plc, Angus Chemical Company and ILC Dover LLC, as well as holding a number of public sector board appointments, including the Strategy Committee of the State Claims Agency and membership of the governing authority at UCD. Julie holds a BSc in Pharmacy from Trinity College Dublin and an MBA from University College Dublin, and is a Chartered Director.
With Julie’s guidance and leadership, NIBRT will continue to deliver world-class biopharma training and research solutions and enter a new stage of growth.
CEO Darrin Morrisey stated, “We are delighted to have Julie leading the organisation as Chairperson. Julie’s extensive experience as a non executive director as well as her expertise in pharmaceutical operations will continue to be a valuable asset to NIBRT, as we strive to deliver on our mission to address the important needs of the biopharmaceutical manufacturing industry through our education, training, and research, and ultimately to help deliver biologic-based medicines to the people who need them.
Julie commented, “I am excited to take on this important role at NIBRT and look forward to working with the team to drive the organination’s mission and future strategy.”
We warmly welcome Julie to her new position and look forward to a successful future under her leadership.